New method to measure antibody drugs in breast cancer without invasive sampling
Official title: Solid Phase Microextraction as a New Tool for Quantifying Antibody Drugs in Breast Cancer and Building PK-PD models
Funded at Albany College of Pharmacy · NIH-10795128 · Data updated 2026-11-12
This study is testing a new, less invasive way to measure how much of a cancer-fighting drug is in breast cancer tumors, so patients won't need to go through blood draws or biopsies, making it easier and safer to track their treatment.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany College of Pharmacy NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | February 5, 2024 |
| Project end | January 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $480,000 |
| NIH project number | 1R15CA287244-01 |
| Project ID | NIH-10795128 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with breast cancer who are undergoing treatment with antibody drugs.
✕Less likely to help
Patients who are not receiving antibody drug therapies or those with non-breast cancer diagnoses may not benefit from this research.
What this research studies
This research focuses on developing a novel technique called solid phase microextraction to measure therapeutic antibody concentrations directly in breast cancer tumors without the need for invasive procedures like blood draws or biopsies. By using innovative microsampling approaches, the study aims to create a more ethical and less risky way to monitor drug levels, which could lead to better treatment outcomes. The methodology seeks to provide real-time data on drug distribution and effectiveness, potentially transforming how breast cancer therapies are monitored and adjusted. This approach addresses significant challenges in pharmacokinetics and pharmacodynamics, particularly for difficult-to-treat cancers.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective monitoring of antibody drug therapies for breast cancer patients.
How similar studies have gone: While the approach of microsampling is innovative, similar techniques in drug monitoring have shown promise in other areas, suggesting potential for success in this novel application.
Where this research is happening
-
Albany College of Pharmacy
Albany, United States Active
Researchers
- Principal investigator: Musteata, Florin Marcel — Albany College of Pharmacy
- Study coordinator: Musteata, Florin Marcel
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.